Correlation Between Viracta Therapeutics and Upstream Bio,

Can any of the company-specific risk be diversified away by investing in both Viracta Therapeutics and Upstream Bio, at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Viracta Therapeutics and Upstream Bio, into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Viracta Therapeutics and Upstream Bio,, you can compare the effects of market volatilities on Viracta Therapeutics and Upstream Bio, and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Viracta Therapeutics with a short position of Upstream Bio,. Check out your portfolio center. Please also check ongoing floating volatility patterns of Viracta Therapeutics and Upstream Bio,.

Diversification Opportunities for Viracta Therapeutics and Upstream Bio,

-0.02

Correlation Coefficient

Viracta Therapeutics  Upstream Bio,

Good diversification

The 3 months correlation between Viracta and Upstream is -0.02. Overlapping area represents the amount of risk that can be diversified away by holding Viracta Therapeutics and Upstream Bio, in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Upstream Bio, and Viracta Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Viracta Therapeutics are associated (or correlated) with Upstream Bio,. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Upstream Bio, has no effect on the direction of Viracta Therapeutics i.e., Viracta Therapeutics and Upstream Bio, go up and down completely randomly.

Pair Corralation between Viracta Therapeutics and Upstream Bio,

Given the investment horizon of 90 days Viracta Therapeutics is expected to generate 1.56 times more return on investment than Upstream Bio,. However, Viracta Therapeutics is 1.56 times more volatile than Upstream Bio,. It trades about 0.21 of its potential returns per unit of risk. Upstream Bio, is currently generating about -0.19 per unit of risk. If you would invest  16.00  in Viracta Therapeutics on October 6, 2024 and sell it today you would earn a total of  6.00  from holding Viracta Therapeutics or generate 37.5% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

Viracta Therapeutics  vs.  Upstream Bio,

Viracta Therapeutics

Risk-Adjusted Performance

2 of 100

Weak

Compared to the overall equity markets, risk-adjusted returns on investments in Viracta Therapeutics are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak basic indicators, Viracta Therapeutics showed solid returns over the last few months and may actually be approaching a breakup point.

Upstream Bio,

Risk-Adjusted Performance

1 of 100

Weak

Compared to the overall equity markets, risk-adjusted returns on investments in Upstream Bio, are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. Despite somewhat uncertain basic indicators, Upstream Bio, may actually be approaching a critical reversion point that can send shares even higher in February 2025.

Pair Trading with Viracta Therapeutics and Upstream Bio,

The main advantage of trading using opposite Viracta Therapeutics and Upstream Bio, positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Viracta Therapeutics position performs unexpectedly, Upstream Bio, can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Upstream Bio, will offset losses from the drop in Upstream Bio,'s long position.

The idea behind Viracta Therapeutics and Upstream Bio, pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.